Background/Aims: Osteoarthritis (OA) is a joint degenerative biomechanical disorder involving immunity, metabolic alterations, inflammation, and cartilage degradation, where chondrocytes play a pivotal role. OA has not effective pharmacological treatments and new therapeutic targets are needed. Adipokines contribute to the low-grade systemic inflammation in OA. Here, we explored novel molecular mechanisms of sodium butyrate (BuNa) in modulating inflammation and chemotaxis in chondrocytes, demonstrating the direct involvement of its G protein-coupled receptor (GPR)-43. Methods: ATDC5 murine chondrocytes were stimulated with interleukin (IL)-1β, in the presence or not of BuNa, for 24 h. RT-PCR and Western blot analysis was performed to evaluate the expression of inflammatory mediators and structural proteins. Results: Butyrate reduced the expression of canonic proinflammatory mediators (Nos2, COX-2, IL-6), pro-inflammatory adipokines (lipocalin-2 and nesfatin-1) and adhesion molecule (VCAM-1 and ICAM-1) in IL-1β-stimulated chondrocytes, inhibiting several inflammatory signalling pathways (NFκB, MAPKinase, AMPK-α, PI3K/Akt). Butyrate also reduced metalloproteinase production and limited the loss of type II collagen in IL-1β-inflamed chondrocytes. The chemoattractant effect of butyrate, after different inflammatory challenges, was revealed by increased annexin (AnxA)1 levels and chemokines expression. The chemoattractant and anti-inflammatory activities of butyrate were completely blunted by GPR43 silencing using RNA interference. Conclusion: Taken together, our data suggest the potential application of sodium butyrate as a novel candidate in a multi-target approach for the treatment of chondrocyte inflammation and cartilage degenerative process.
Butyrate Modulates Inflammation in

Introduction
Osteoarthritis (OA) is the most common rheumatic disease and a major cause of pain and chronic disability in adults. OA development is strongly influenced by ageing, obesity and biomechanical injury [1] . Although OA involves whole joint structures and is characterized by a progressive degradation of the articular cartilage, the pivotal role of chondrocytes is related not only to the impaired production/responsiveness to catabolic, anabolic and inflammatory stimuli but also to the failed repair of cartilage matrix damage [2] .
IL-1β is a cytokine that plays a pivotal role in the inflammatory response and catabolic events in chondrocytes [3, 4] eliciting the synthesis of prostaglandins by cyclooxygenases (COXs) [5] and the activation of several cytoplasmic protein kinases (MAPK, ERK 1/2 and p38 kinase) [6] . The activation of these kinases drives specific signalling pathways that increase the DNA binding activity of NF-κB and AP-1, both factors implicated in the transcription of pro-inflammatory genes, such as COX-2 and Nos2 [7] . Additionally, these factors also promote the transcription of catabolic genes such as matrix metalloproteinases (MMPs), which are involved in OA-associated degradative process [8] .
The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been the major pharmacologic approach to treating the symptoms of degenerative and inflammatory arthropathies [9] , even though these drugs fail to modify the degenerative processes. Although considerable progress has been made in the development of novel pharmacological strategies, such as the MMP inhibitors [10] , no clinically effective inhibitor exists to date. The search for alternative and/or complementary anti-inflammatory agents that might counteract the joint degenerative processes and the resulting injury is thus of paramount importance.
The identification of novel therapeutic properties of active compounds targeting multiple pathways could provide an alternative to conventional treatment of OA [11] . Toward this goal, recent studies suggest that natural products that are rich in antioxidant and antiinflammatory compounds might contribute to the prevention of inflammatory diseases such as OA [12] .
Butyrate is a short-chain fatty acid (SCFA), mainly produced from undigested fibres metabolically fermented in the large intestine, and is considered the major energy source for colonocytes, maintaining intestinal homeostasis and functions [13] .
Recent experimental evidence suggested different therapeutic applications for butyrate, including its ability to treat metabolic and inflammatory diseases [14, 15] . Butyrate effects include epigenetic modifications due to its inhibitory effects on histone deacetylases (HDAC), inhibition of NF-κB signalling [16] , and the direct agonism on the SCFA G-protein coupled receptors, GPR41 and GPR43 [17] . Butyrate is also involved in the activation of peroxisome proliferator-activated receptors (PPARs), a class of nuclear receptors that modulate inflammation, pain, and nociception [18] . Clinical trials in patients with inflammatory bowel diseases evidenced the anti-inflammatory effect of butyrate, by suppressing mucosal inflammation and NF-kB activation in lamina propria macrophages [19, 20] . Finally, immunomodulatory effects of butyrate on neutrophil chemotaxis, mediated by its receptors on immune cells, have been also described [21, 22] .
In the past, some beneficial effects of butyrate have been determined in chondrocytes [5, 23] , but the complete mechanism of its anti-inflammatory activity was overlooked. The aim of this study was to evaluate novel molecular mechanisms of butyrate as a modulator of inflammation and regenerative process in chondrocytes. 
Materials and Methods
Cell culture
The murine chondrogenic cell line ATDC5 (purchased from RIKEN Cell Bank, Tsukuba, Japan) was cultured as previously [7] , and allowed to differentiate into mature chondrocytes [24] . All reagents were purchased from Sigma (Missouri, USA) unless otherwise specified.
Cell viability and nitrite assay
Cell metabolic activity was examined using a colorimetric assay based on the MTT labeling reagent. Cells were seeded in 96-well plates (8, 000 cells/well) and pre-treated with 250 µM BuNa (Sigma-Aldrich) for 1 hour; then, IL-1β (0.5 ng/ml) was added for 24 h. Assays were performed according to the instructions and protocol provided by the manufacturer (Sigma-Aldrich). Spectrophotometrical absorbance was measured using a microtiter ELISA reader at 550 nm (Multiskan EX, Termo Labsystem, Barcelona, Spain).
Nitrite accumulation was measured in the culture medium by Griess reaction. Briefly, 100 µl of cell culture medium was mixed with 100 μl of Griess reagent (equal volumes of 1% [weight/volume] sulfanilamide in 5% [volume/volume] phosphoric acid and 0.1% [w/v] naphtylethylenediamine HCl), incubated at room temperature for 10 minutes, and then the absorbance at 550 nm was measured in a microplate reader (Titertek Multiscan; Labsystems, Helsinki, Finland). Fresh culture medium was used as blank in all the experiments. The amount of nitrite in the samples (in µM) was calculated from a sodium nitrite standard curve freshly prepared in culture medium.
Western blot analysis
Cells were seeded in P6 multiwell plates at a density of 10 6 cells/well and then incubated overnight in serum-free conditions. To determine Nos2, VCAM-1, and lipocalin-2 (LCN2) protein expression, ATDC5 cells were pre-treated with 250 µM BuNa (Sigma-Aldrich) for 1 hour; then, IL-1β (0.5 ng/ml) was added for 24 h, the time selected for optimal observation according to our time-course experiments. To evaluate NfκB p65 translocation and IκB-α degradation, the phosphorylation of ERK1/2, p38 subunit, Akt, and AMPKα, cells were pre-treated with BuNa for 12 hours and then challenged with IL-1β for 15 or 30 min. Afterward, cells were subjected to a differential lysis to obtain the nuclear and cytosolic fractions as previously described [25] . Blots were incubated with the appropriate antibodies: anti-iNOS and anti-VCAM-1 (Cell Signaling Technology, Denver, Massachusetts, USA), lipocalin-2 (R&D Systems, Inc., Minneapolis, MN, USA), antiphospho ERK1/2, anti-ERK1/2, anti-phospho-p38 and anti-p38 (Millipore, MA, USA), anti-NFκB p65 (Santa Cruz, CA, USA), anti-IκB-α, anti-phospho-Akt and anti-Akt, anti-phospho-AMPKα and anti-AMPKα (Cell Signaling Technology, Denver, Massachusetts, USA). Immunoblots have been visualized with Immobilon Western Detection Kit (Millipore, MA) using horseradish peroxidase labelled secondary antibody. To confirm equal loading in each sample, the membranes were stripped in stripping buffer (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7) and re-blotted with anti-GAPDH (Sigma, MO, USA) or anti-lamin-β1 antibody (GeneTex, CA, USA). The images were captured and analyzed with an EC3 imaging system (UVP). Densitometric analyses were performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
RNA isolation and Real-Time PCR analysis
RNA was extracted using a NucleoSpin kit, according to the instructions and protocol provided by the manufacturer. For relative quantification, we performed an RT reaction with a First Strand Kit from SABiosciences. Next, real-time PCR was performed with an SABiosciences Master Mix and specific RT 2 qPCR primers, as reported in Table 1 . Results of comparative Real-Time PCR were analyzed with MxPro version 4 software (Stratagene, La Jolla, CA).
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siRNA-mediated gene silencing of GPR43 receptor
In order to silence GPR43 gene, we used the siRNA that targets GPR43 receptor (siGpr43, Integrated DNA Technologies, USA) and the siRNA negative control, that does not target any known sequence. Transfection with 10nM of siRNA duplex was performed using the cationic lipid siLentFect (BioRad, CA, USA) according to the manufacturer's recommendations. Cells were transfected for 48 h and then they were stimulated with 0.5 ng/ml of IL1β in the presence or not of 250 µM BuNa for 24 h.
Statistical analysis
Data are reported as mean ± S.E.M. values of independent experiments, which were done at least three times, each time with three or more independent observations. Statistical analysis was performed by analysis of variance test, and multiple comparisons were made by Bonferroni's test. Data sets have been tested for normality by Shapiro-Wilks test (all the data sets passed this test). Statistical significance was set at P<0.05.
Results
Butyrate reduces pro-inflammatory mediators and adipokines in IL-1β-stimulated chondrocytes
Butyrate concentration at 250 µM was chosen based on data obtained on cell viability and on its efficacy in reducing IL1β-stimulated nitrite production ( Fig. 1A and Fig. 1B,  respectively) .
As shown in Fig. 2 , the anti-inflammatory effect of butyrate on IL-1β -induced Nos2 synthase, Ptgs2, Il6 mRNA expression was analysed in ATDC5 chondrogenic cells. Under basal conditions, the mRNA levels of all these pro-inflammatory mediators were undetectable. IL-1β stimulation of ATDC5 cells induced a significant increase of all these genes.
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Butyrate at 250 µM was able to markedly suppress this induction, suggesting that its anti-inflammatory effect was at the transcriptional level ( Fig. 2A-C) , also confirmed by Nos2 Western Blot analysis (Fig. 2D ).
For completeness, we also examined protein and mRNA expression of two relevant adipokines (LCN2 and NUCB2) involved in the regulation of inflammatory response elicited by IL-1β in chondrocytes. As shown in Fig. 2E and Fig. 2F , BuNa was able to significantly decrease NUCB2 mRNA levels and the expression of lipocalin-2.
Butyrate reduces adhesion molecule expression
The vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 mediate the adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium and may play a role in the development of a rheumatic disease [26] . As shown in Fig. 3A and Fig. 3B , IL-1β was able to strongly induce both Icam1 and Vcam1 mRNA expression. Butyrate significantly decreased the expression of both adhesion molecules mRNAs induced by IL-1β. This effect was also observed in terms of VCAM-1 protein expression as shown in Fig. 3C .
Effect of butyrate on pro-inflammatory signalling pathways
In response to inflammatory stimuli, the p65 subunit of NfκB is activated and translocated into the nucleus whereas IκB-α is degraded at the cytoplasm. In our experiments, after IL-1β stimulation for 15-30 minutes, the activation of the p65 subunit and consequently IκB-α degradation was observed. Butyrate, on IL-1β-stimulated ATDC5 cells, significantly reduced NFκB p65 expression and consistently increased IκB-α (Fig. 4A and Fig. 4B ).
Butyrate also significantly decreased IL-1β-induced phosphorylation of ERK1/2 and p38 kinases suggesting that its anti-inflammatory effect involved the inactivation of the MAP-kinase signalling pathway (Fig. 4C and Fig. 4D) .
It is well known that IL-1β induces the phosphorylation and activation of AMP-activated protein kinase (AMPK)-α, an enzyme that works as a metabolic switcher, modulating cell homeostasis. As shown in Fig. 4E , the phosphorylation of AMPKα was significantly increased by IL-1β stimulation compared with no-treated cells. On the contrary, sodium butyrate markedly reduced this phosphorylation (Fig. 4E) . Similarly, butyrate strongly decreased the phosphorylation of Akt (Fig. 4F) .
Effect of butyrate on MMP-13 production and type II collagen levels after inflammatory stimulation Cartilage destruction in OA is thought to be mediated mainly by MMPs, which are responsible for collagen breakdown in the joint cartilage [27] . IL-1β stimulation produced a marked increase of MMP13 mRNA (Fig. 5A) and consistently a reduction of type II collagen (Col2a1) levels (Fig. 5B) . However, BuNa decreased MMP13 mRNA expression and limited the reduction of Col2a1, altered by IL-1β.
Butyrate potentiates chemokine expression after different inflammatory challenges
In ATDC5 cells, IL-1β has been described as a potent inducer of relevant chemokines involved in inflammatory processes and in neutrophils and leucocytes recruitment, such as Ccl3 and Cx3cl1. Similarly, IL-1β induces annexin-1 (AnxA1), a protein that inhibits various inflammatory events, including chemotaxis.
As shown in Fig. 6A and Fig. 6C , IL-1β efficiently induced the expression of Ccl3 and Cx3cl1. BuNa, when used in combination with IL-1β, further increased the chemotactic effect elicited by this cytokine. The effect of butyrate was observable even when the cells were challenged with other pro-inflammatory stimuli such as TNFα (Fig. 6D) or TLR4 agonists such as LPS (Fig. 6B and Fig. 6E) . Notably, BuNa is also able to potentiate the transcription of AnxA1 in ATDC5 cells (Fig. 6F) . All data obtained on ATDC5 chondrogenic cells were confirmed on totally differentiated ATDC5 cells, after 14 days of cell differentiation (Fig. 7A-F) , that have been demonstrated to have the same phenotype of human mature chondrocytes [28, 29] .
Role of GPR43 receptor in butyrate chemoattractant and anti-inflammatory activity
To clarify the potential mechanism of butyrate chemoattractant and anti-inflammatory activities, we hypothesized that these effects were modulated, totally or in part, by GPR43, the main butyrate receptor. As shown in Fig. 8A-D 
Discussion
OA is commonly considered a disease in which inflammatory, biomechanical, metabolic and also immune mechanisms impacted on the whole joint [30] , in which the chondrocyte is regarded as the major actor [31] . Several risk factors, including obesity, ageing, and metabolic disorders promote pathogenesis and progression of this disease. Even if huge advancements have been made, in terms of identification and characterization of the molecular and cellular basis of OA, this disease remains still orphan of effective anti-inflammatory treatments that can limit the cartilage degenerative processes and the resulting lesions.
In this study, we demonstrated that, in IL-1b-stimulated chondrocytes, butyrate not only reduces pro-inflammatory mediators, adipokines and adhesion molecules, inhibiting several inflammatory signalling pathways, but also limits metalloproteinase production and the loss of type II collagen, highlighting the relevant role of GPR43 receptor in its antiinflammatory and chemoattractant activity. Although butyrate can modulate inflammation in intestinal and extra-intestinal diseases [14] , only a little evidence showed the beneficial effect of butyrate in rheumatic disorders. Several years ago, the efficacy of butyrate in human chondrocytes was evidenced, suppressing the expression of pro-inflammatory mediators or destructive MMPs [5, 23] , whereas more recently, the utility of butyrate treatment on acute gouty arthritis has been assessed [32] . Nevertheless, the mechanism/s by which butyrate might exert its beneficial effect in the treatment of OA, and related disorders, is still elusive and need further investigations. There is a bulk of evidence pointing to the relevance of inflammation in the development and progression of OA [2] . This relevance has been supported through the association of joint effusion with joint pain [33] and the significant production of several pro-inflammatory mediators [34] . In particular, IL-1β plays a central role in the pathophysiology of OA [3] . In fact, IL-1b induces a cascade of inflammatory and catabolic events in chondrocytes, including the synthesis of prostaglandin E2 (PGE2) and NO [5] . In our experimental conditions, chondrocyte stimulation with this cytokine showed increased nitrite accumulation and Nos2 induction, in agreement with previous studies [35, 36] . Moreover, butyrate reduces nitric oxide production, COX-2, and IL-6 induction and modulates inflammatory adipokines, such as LCN2 and NUCB2.
Recently, we demonstrated the beneficial effect of butyrate in a mice model of dietinduced obesity, not only on the weight loss, but also restoring adipokine dysfunction, and reducing inflammation [15] . Interestingly, adipokine dysregulation is a clear component of metabolic-triggered inflammation in OA and RA [30, 37] . For instance, our group recently demonstrated that lipocalin-2 was implicated in human and murine chondrocyte pathophysiology, being it highly expressed in hypertrophic cells [28, 38] . LCN2 is modulated by several factors, including IL-1β, and increased in different rheumatic diseases [28] . It has been demonstrated that the human neutrophil gelatinase-associated lipocalin can contribute to cartilage matrix degradation in OA, by protecting MMP-9 activity [39] . Similarly, another novel adipokine, NUCB2, is involved in rheumatic disorders, in cartilage maturation and in the complex mechanisms of chondrocyte development and differentiation, with strong metabolic actions similar to those exerted by other members of adipokine superfamily [40] . Here, butyrate dampened the IL-1β-induced increase of LCN2 and NUCB2, showing its ability to modulate the adipokine network also in inflamed chondrocytes.
During inflammation, adhesion molecules, whose expression is mainly regulated by inflammatory cytokines, facilitate the recruitment of circulating leukocytes to the sites of damage [41, 42] . In severe OA, high levels of soluble VCAM-1 were linked to the risk of hip and knee joint replacement [26] . Our data show that, in IL-1β-challenged chondrocytes, the expression of VCAM-1 and ICAM-1 was strongly decreased by butyrate, confirming its antiinflammatory effect in limiting leukocyte recruitment.
In articular chondrocytes, IL-1β was able to trigger MAPKinases signalling pathways, which in turn may lead to NF-κB and AP-1 activation in the synovium of patients with RA and OA [43] . Hence, we investigated the effect of butyrate on the PI3-kinase/Akt pathway, whose inhibition blocks the activation of other convergent or downstream pathways, including ERK/MAPKinase [44] . Our data indicate that butyrate could modulate the intracellular inflammatory signalling in damaged cartilage, inhibiting IL-1β-induced Akt activation and MAPK signalling.
It has been also demonstrated that IL-1b and hydrogen peroxide caused the activation of the redox-dependent transcription of NF-κB and AP-1 in bovine chondrocytes [45] . This effect triggers a remarkable decrease in type II collagen transcription, associated with a significant increase in MMP synthesis [45] , leading to the onset of cartilage structural damage. Moreover, Terkeltaub et al. [46] showed that IL-1β and TNFα induced the expression of important metalloproteinases, such as MMP-3 and MMP-13. IL-1β stimulation induced a marked increase of MMP13 and the reduction of type II collagen in both undifferentiated and differentiated chondrocytes. These modifications were strongly counteracted by butyrate, highlighting, in addition to the anti-inflammatory effect, its capability in limiting extracellular matrix disruption and consequentially in reducing the loss of collagen, an important structural protein of healthy cartilage.
As known, the inflammatory response promotes the increased release of chemokines, which, acting as chemoattractants, guide cells toward the site of injury. Among these, fractalkine, or Cx3cl1, was significantly elevated in patients with knee OA [47] . Furthermore, these chemokines in OA patients might contribute to the unbalance between anabolism and catabolism of cartilage and chondrocytes [27, 48] . Interestingly, we observed that chemokine release by different inflammatory challenges was further increased by butyrate Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry treatment. This result suggests a potential contribution of butyrate in the inflammatory resolution. The resolution process is mediated by several factors, including AnxA1 [49] . Recent data demonstrated the positive correlation between HDACs inhibitors and the anti-inflammatory and pro-resolving AnxA1 [50] . Defective inflammation resolution or its dysregulation is involved in several chronic inflammatory disease including arthritis, asthma and cardiovascular disease [51] . Emerging evidence indicate that unbalance between specialized pro-resolving and pro-inflammatory mediators are associated with several human diseases. However, mechanisms that drive this unbalance remain largely unknown. In some cases, AnxA1 is up-regulated in human blood and tissues but fail to engage in proresolving signalling and, hence, to regulate excessive inflammation [52] . Our data show an increase of AnxA1 induced by butyrate, suggesting a likely role for this molecule in promoting the resolution of inflammation, reducing the unbalance between pro-inflammatory and anti-inflammatory mediators. These effects of butyrate have been also confirmed in totally differentiated ATDC5 cells after 14 days of cell differentiation, showing that the efficacy of butyrate does not depend on chondrocyte differentiation status. Interestingly, it has been demonstrated that these differentiated cells have a phenotype identical to human mature chondrocytes [28, 29] . Another novelty of this study was to determine the involvement of butyrate GPR43 receptor in chondrocyte IL-1β-induced inflammation and chemotaxis. Actually, butyrate completely fails in chemokine and AnxA1 induction after GPR43 gene silencing. Previous studies demonstrated the relevant in vitro and in vivo role of GPR43 on immune cells and on SCFA-induced neutrophil chemotaxis [22] . This is the first time that GPR43 has been described as target of butyrate activity in chondrocytes. Moreover, after GPR43 silencing, butyrate was unable to reduce NOS type II and IL-6, strengthening the involvement of this receptor in butyrate modulation of chemotactic factors as well as inflammatory mediators. However, the involvement of other butyrate receptors or alternative molecular mechanisms in the effects of butyrate cannot be excluded.
Conclusion
In conclusion, our data define a novel GPR43-mediated anti-inflammatory mechanism of butyrate in chondrocytes. Butyrate reduced pro-inflammatory mediators, adhesion molecules and inhibited novel OA-linked inflammatory adipokines. All these effects are correlated with the inhibition of the most important inflammatory signalling pathways (i.e. NF-κB, ERK/MAPKinase, PI3kinase/Akt, AMPK). Butyrate also could promote the maintenance of cartilage integrity and homeostasis, limiting extracellular matrix disruption and the loss of type II collagen. Finally, we demonstrated the essential role of GPR43 in butyrate activity. The efficacy of this endogenous molecule in reducing inflammation in chondrocytes together with its chemoattractant effect may suggest its potential systemic or local application as multi-target approach for the management of chondrocyte inflammation, mainly responsible for cartilage degeneration in OA.
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